Page 1

Personalis Personalis Reports First Quarter 2021 Financial Results May 5 , 2021 MENLO PARK , Calif .-- ( BUSINESS WIRE ) -- May 5 , 2021 -- Personalis , Inc. ( Nasdaq : PSNL ) , a leader in advanced genomics for population sequencing and cancer , today reported financial results for the first quarter ended March 31 , 2021 . First Quarter Highlights • Record quarterly revenue of $ 20.9 million in the first quarter of 2021 compared with $ 19.2 million in the first quarter of 2020 , a 9 % increase • Revenue of $ 7.7 million from biopharma and all other customers , excluding VA MVP , in the first quarter of 2021 compared with $ 4.4 million in the first quarter of 2020 , a 74 % increase • Announced a collaboration with Natera in the field of personalized oncology ; Personalis to provide the exome sequence data for Natera to pair with their personalized ctDNA platform , Signatera T TM • Announced a collaboration with MapKure , LLC , a company jointly owned by BeiGene , Ltd. and SpringWorks Therapeutics , Inc. , LLC for use of the NeXT Platform TM for clinical trials and companion diagnostic development • Added approximately $ 162 million of cash to balance sheet from public offering of common stock financing in the first quarter of 2021 ; ended the quarter with cash , cash equivalents , and short - term investments of $ 353.4 million as of March 31 , 2021 " I'm proud to say that we were able to report record revenue once again this quarter and achieved our nineteenth consecutive quarter of growth , as we converted an increasing number of orders into revenue . Biopharma and all other customer revenue grew 74 % year - over - year , and orders from customers exceeded revenues reported once again this quarter , " said John West , Chief Executive Officer . " Recently , we announced a partnership with Natera in the field of personalized oncology , and a companion diagnostics collaboration with MapKure . Both collaborations further validate our NeXT platform as a leading front end tissue - sequencing platform , capable of detecting cancer cell mutations that conventional exome tests often miss . Our tissue offering complements our whole exome liquid biopsy product that we launched in August 2020 and NeXT Personal , our Minimal Residual Disease ( MRD ) offering that we expect to launch in 2021 , providing Personalis with access to three distinct revenue opportunities in the rapidly growing cancer monitoring market . " First Quarter 2021 Financial Results Revenues were $ 20.9 million in the three months ended March 31 , 2021 , up 9 % from $ 19.2 million in the same period of the prior year . Gross margin was 35.6 % in the three months ended March 31 , 2021 , compared with 21.1 % in the same period of the prior year . Operating expenses were $ 19.9 million in the three months ended March 31 , 2021 , compared with $ 13.7 million in the same period of the prior year . Net loss was $ 12.4 million in the three months ended March 31 , 2021 and net loss per share was $ 0.29 based on a weighted - average basic and diluted share count of 42.3 million , compared with a net loss of $ 9.1 million and a net loss per share of $ 0.29 on a weighted - average basic and diluted share count of 31.3 million in the same period of the prior year . Business Outlook Personalis expects the following for the second quarter of 2021 : • Total Company revenues to be approximately $ 21.3 million • Revenues from biopharma and all other customers , excluding VA MVP , to be in the range of $ 7.3 million to $ 7.7 million • Net Loss to be in the range of $ 16 million to $ 17 million ; estimated outstanding shares of 43 million Personalis expects the following for the full year of 2021 : • Total Company revenues to be approximately $ 85 million • Revenues from biopharma and all other customers , excluding VA MVP , to be in the range of $ 30 million to $ 32 million • Net Loss to be in the range of $ 70 million to $ 75 million ; estimated outstanding shares of 44 million Webcast and Conference Call Information Personalis will host a conference call to discuss the first quarter 2021 financial results after market close on Wednesday , May 5 , 2021 at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time . The conference call can be accessed live over the phone by dialing ( 866 ) 220-8061 for U.S. callers or ( 470 ) 495-9168 for international callers , using the conference ID : 6587766. The live webinar can be accessed at https : // investors personalis.com . About Personalis , Inc. Personalis , Inc. is a leader in population sequencing and cancer genomics , with a focus on data , scale , efficiency and quality . Personalis operates one